all ( 14 results found)

Sort by:

Date Last Updated:

Medicine Status DHPC Document Name Additional Communications Company Kymriah 1.2 x 106 – 6 x 108 cells dispersion for infusion
Updated

DHPC - Risk of secondary malignancy of T-cell origin in CD19- or BCMA-directed CAR T-cell therapies

Novartis Ireland Limited
Dzuveo 30 micrograms sublingual tablet
No Recent Update

Dzuveo cover letter

Dzuveo DHCP letter

Aguettant Ltd
Epipen Junior 150 micrograms solution for injection in pre-filled pen
No Recent Update

EpiPen® Healthcare Professional Letter

Mylan IRE Healthcare Ltd
Epipen 300 micrograms solution for injection in pre-filled pen
No Recent Update

EpiPen® Healthcare Professional Letter

Mylan IRE Healthcare Ltd
Quinsair 240 mg nebuliser solution
No Recent Update

Fluoroquinolones DHPC_HPRA_FINAL vs2 30-05-23

Chiesi Limited
Infanrix Hexa, Powder and suspension for suspension for injection
No Recent Update

Infanrix Hexa - DHPC

GlaxoSmithKline (Ireland) Ltd
Topamax Sprinkle 25 mg hard capsules
No Recent Update

Topiramate: New restrictions to prevent exposure during pregnancy

Janssen Sciences Ireland (a Johnson & Johnson Company)
Topamax Sprinkle 15 mg hard capsules
No Recent Update

Topiramate: New restrictions to prevent exposure during pregnancy

Janssen Sciences Ireland (a Johnson & Johnson Company)
Topamax 50mg film-coated tablets
No Recent Update

Topiramate: New restrictions to prevent exposure during pregnancy

Janssen Sciences Ireland (a Johnson & Johnson Company)
Topamax 25mg film-coated tablet
No Recent Update

Topiramate: New restrictions to prevent exposure during pregnancy

Janssen Sciences Ireland (a Johnson & Johnson Company)
Topamax 200mg film-coated tablets
No Recent Update

Topiramate: New restrictions to prevent exposure during pregnancy

Janssen Sciences Ireland (a Johnson & Johnson Company)
Topamax 100mg film-coated tablets
No Recent Update

Topiramate: New restrictions to prevent exposure during pregnancy

Janssen Sciences Ireland (a Johnson & Johnson Company)
Vabysmo 120 mg/mL solution for injection
No Recent Update

Vabysmo DHPC dated 17 Oct 2024

Roche Registration GmbH
Zolgensma 2 × 1013 vector genomes/mL solution for infusion
No Recent Update

Zolgensma (onasemnogene abeparvovec): Important Safety Information

Novartis Ireland Limited